1 |
Williams SC, Frew JW, Krueger JG. A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa. Exp Dermatol 2021;30:1388-97. [PMID: 32614993 DOI: 10.1111/exd.14141] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
2 |
Holcomb ZE, Porter ML, Kimball AB. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. Expert Opin Drug Saf 2021;:1-15. [PMID: 33910441 DOI: 10.1080/14740338.2021.1924147] [Reference Citation Analysis]
|
3 |
Odorici G, Pacetti L, Forconi R, Schettini N, Zedde P, Corazza M, Bettoli V. Seven Years-Experience of adalimumab therapy for hidradenitis suppurativa in a real-life dermatologic setting. J Dermatolog Treat 2021;:1-10. [PMID: 33843413 DOI: 10.1080/09546634.2021.1914309] [Reference Citation Analysis]
|
4 |
Das K, Daveluy S, Kroumpouzos G, Agarwal K, Podder I, Farnbach K, Ortega-Loayza AG, Szepietowski JC, Grabbe S, Goldust M. Efficacy and Toxicity of Classical Immunosuppressants, Retinoids and Biologics in Hidradenitis Suppurativa. J Clin Med 2022;11:670. [PMID: 35160122 DOI: 10.3390/jcm11030670] [Reference Citation Analysis]
|
5 |
Molinelli E, Sapigni C, Campanati A, Brisigotti V, Offidani A. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa. Expert Opin Drug Metab Toxicol 2020;16:1019-37. [PMID: 32896186 DOI: 10.1080/17425255.2020.1810233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|